This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
XELJANZ® (tofacitinib citrate) Prescribing Information and Maxtrex (methotrexate) Prescribing Information. Adverse event reporting can be found at the bottom of the page.
Tofacitinib should only be used if no suitable treatment alternatives are available in patients:
These risks are considered class effects and relevant across all approved indications of JAKi in inflammatory and dermatologic diseases.
Adapted from Deodhar et al. 2021.
FAS; MMRM used without imputation for missing values
* P<0.001 vs placebo
† P≤0.05 vs placebo, according to the prespecified step-down testing procedure for control of ASAS components
A 48-week, randomized, phase 3 study (consisting of a 16-week double-blind phase, followed by a 32-week open-label phase) including 269 adult patients with active AS and an inadequate response to ≥2 NSAIDs. Randomization was stratified by bDMARD treatment history in patients who had inadequate response to ≤2 TNFis or had prior bDMARD (TNFi or non-TNFi) use without IR. At baseline, 207 patients were bDMARD-naïve, and 62 patients were TNFi-IR or prior bDMARD use (non-IR). NSAIDs/COX-2 inhibitors, MTX, SSZ, or oral corticosteroids were allowed if patients were on a stable dosage at baseline. For patients taking XELJANZ®, the mean age was 42.2 years old (40 years old for placebo), and most patients were male (87.2% for XELJANZ 5 mg BID, 79.4% for placebo). Patients taking XELJANZ in the trial had a mean disease duration since symptoms of 14.2 years (12.9 years for placebo), AS disease duration since diagnosis: mean 8.9 years (6.8 for placebo), and mean baseline BASDAI score: 6.4 (6.5 for placebo).
The primary endpoint was to evaluate the proportion of patients who achieved an ASAS20 response at week 16. To control for type I error at the 5% level for primary and certain secondary endpoints, 4 families of efficacy endpoints were tested in hierarchical sequences with a step-down approach. The first family, the global type I error–controlled endpoints at week 16, included: ASAS20 response; ASAS40 response; ΔASDAS(CRP); ΔhsCRP, ΔASQoL, ΔSF-36v2 PCS score, ΔBASMI, and ΔFACIT-F total score. Upon meeting statistical significance for ASAS20 response at week 16, the second family included ΔASAS components at week 16, and included testing for ΔPtGA, Δtotal back pain, ΔBASFI, and Δmorning stiffness (inflammation). The third family, ASAS20 response over time, and the fourth family, ASAS40 response over time, were each tested in the following sequence: weeks 16, 12, 8, 4, and 2. In each family, statistical significance could be declared only if the prior endpoint (or time point) in the sequence met the requirements for significance. Nonresponder imputation was applied to missing data for ASAS response rates.
Δ=change from baseline; AS=ankylosing spondylitis; ASAS=Assessment of SpondyloArthritis international Society; ASDAS(CRP)=Ankylosing Spondylitis Disease Activity Score based on C-reactive protein; ASQoL=Ankylosing Spondylitis Quality of Life; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; BASMI=Bath Ankylosing Spondylitis Metrology Index; bDMARD=biologic disease-modifying antirheumatic drug; BID=twice daily; COX-2=cyclooxygenase 2; CRP=C-reactive protein; FACIT-F=Functional Assessment of Chronic Illness Therapy-Fatigue; FAS=full analysis set; hsCRP=high-sensitivity C-reactive protein; IR=inadequate response; JAKi=Janus kinase inhibitor; LS=least squares; MMRM=mixed model for repeated measures; MTX=methotrexate; N1=number of patients with observation at visit; NSAID=nonsteroidal anti-inflammatory drug; PtGA=Patient Global Assessment of Disease Activity; SD=standard deviation; SF-36v2 PCS=Short Form-36 Health Survey Version 2 Physical Component Summary; SSZ=sulfasalazine; TNFi=tumor necrosis factor inhibitor.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024